Trial Profile
Open-label Study of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Undergoing Treatment Programs in Comparison With Control Group
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary) ; Ciclosporin
- Indications Iron overload
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 08 Jul 2019 Status changed from completed to discontinued.
- 20 Apr 2017 Status changed from recruiting to completed.
- 11 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 as per ClinicalTrials.gov record.